The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

The FDA granted fast track designation (FTD) to IBI3003, a first-in-class trispecific antibody, for the treatment of patients ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has changed dramatically over the past decade, resulting in more therapeutic options for various stages of relapse. In a ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...

SAN FRANCISCO and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

A Prescription Drug User Fee Act target date of July 10, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...